questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Receptor-Like Protein Tyrosine Phosphatases
Receptor-Like Protein Tyrosine Phosphatases, Class 1
Antigènes CD45
Antigènes CD45 : Questions médicales fréquentes
Diagnostic
5
Antigènes CD45
Cytométrie en flux
Tests immunologiques
Analyse sanguine
Maladies auto-immunes
Cancers
Biopsies
Immunohistochimie
Symptômes
5
Troubles immunitaires
Hématologie
Réponse immunitaire
Lymphocytes
Troubles neurologiques
Études
Prévention
5
Prévention
Maladies auto-immunes
Dépistages
Suivis réguliers
Alimentation
Santé immunitaire
Stress
Fonction immunitaire
Traitements
5
Immunosuppresseurs
Thérapies ciblées
Transfusions sanguines
Leucocytes
Thérapies géniques
Anomalies
Traitements personnalisés
Profil CD45
Médicaments immunomodulateurs
Réponse immunitaire
Complications
5
Infections récurrentes
Troubles hématologiques
Risque de cancer
Cancers hématologiques
Transplantation
Compatibilité
Complications réversibles
Traitement approprié
Complications neurologiques
Études
Facteurs de risque
5
Antécédents familiaux
Infections chroniques
Maladies chroniques
Réponse immunitaire
Stress psychologique
Santé immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigènes CD45 : Questions médicales les plus fréquentes",
"headline": "Antigènes CD45 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigènes CD45 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2026-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigènes CD45"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Receptor-Like Protein Tyrosine Phosphatases, Class 1",
"url": "https://questionsmedicales.fr/mesh/D054622",
"about": {
"@type": "MedicalCondition",
"name": "Receptor-Like Protein Tyrosine Phosphatases, Class 1",
"code": {
"@type": "MedicalCode",
"code": "D054622",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.733.937"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigènes CD45",
"alternateName": "Leukocyte Common Antigens",
"code": {
"@type": "MedicalCode",
"code": "D017493",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Lisa M James",
"url": "https://questionsmedicales.fr/author/Lisa%20M%20James",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA."
}
},
{
"@type": "Person",
"name": "Apostolos P Georgopoulos",
"url": "https://questionsmedicales.fr/author/Apostolos%20P%20Georgopoulos",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA. omega@umn.edu."
}
},
{
"@type": "Person",
"name": "Wei-Ya Li",
"url": "https://questionsmedicales.fr/author/Wei-Ya%20Li",
"affiliation": {
"@type": "Organization",
"name": "Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China."
}
},
{
"@type": "Person",
"name": "Xue Tang",
"url": "https://questionsmedicales.fr/author/Xue%20Tang",
"affiliation": {
"@type": "Organization",
"name": "Tasly Research Institute, Tasly Holding Group Co., Ltd, Tianjin, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Human leukocyte antigen-G in gynaecological tumours.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37415092",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/iji.12626"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prediction of KIR3DL1/Human Leukocyte Antigen binding.",
"datePublished": "2024-05-05",
"url": "https://questionsmedicales.fr/article/38746109",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2024.05.03.592082"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of Human Leukocyte Antigen (HLA) class II (",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37426636",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1178546"
}
},
{
"@type": "ScholarlyArticle",
"name": "Enterobacterial common antigen biosynthesis in",
"datePublished": "2023-08-26",
"url": "https://questionsmedicales.fr/article/37662240",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2023.08.26.554945"
}
},
{
"@type": "ScholarlyArticle",
"name": "Repeated human leukocyte antigens eplets, importance of typing the partner.",
"datePublished": "2024-05-08",
"url": "https://questionsmedicales.fr/article/38729449",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.trim.2024.102049"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Receptor-Like Protein Tyrosine Phosphatases",
"item": "https://questionsmedicales.fr/mesh/D054557"
},
{
"@type": "ListItem",
"position": 6,
"name": "Receptor-Like Protein Tyrosine Phosphatases, Class 1",
"item": "https://questionsmedicales.fr/mesh/D054622"
},
{
"@type": "ListItem",
"position": 7,
"name": "Antigènes CD45",
"item": "https://questionsmedicales.fr/mesh/D017493"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigènes CD45 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigènes CD45",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigènes CD45",
"description": "Comment diagnostiquer une anomalie des antigènes CD45 ?\nQuels tests sont utilisés pour évaluer les CD45 ?\nLes CD45 sont-ils impliqués dans des maladies spécifiques ?\nQuelle est l'importance des CD45 dans le diagnostic ?\nPeut-on détecter les CD45 dans les biopsies ?",
"url": "https://questionsmedicales.fr/mesh/D017493#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigènes CD45",
"description": "Quels symptômes sont associés aux anomalies des CD45 ?\nLes anomalies des CD45 provoquent-elles des symptômes spécifiques ?\nComment les CD45 affectent-ils la réponse immunitaire ?\nLes symptômes varient-ils selon le type de CD45 ?\nLes CD45 sont-ils liés à des symptômes neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D017493#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigènes CD45",
"description": "Peut-on prévenir les anomalies des CD45 ?\nLes vaccinations influencent-elles les CD45 ?\nY a-t-il des mesures préventives spécifiques pour les CD45 ?\nL'alimentation affecte-t-elle les CD45 ?\nLe stress influence-t-il les CD45 ?",
"url": "https://questionsmedicales.fr/mesh/D017493#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigènes CD45",
"description": "Quels traitements ciblent les anomalies des CD45 ?\nLes transfusions sanguines affectent-elles les CD45 ?\nComment les thérapies géniques influencent-elles les CD45 ?\nLes traitements sont-ils personnalisés selon les CD45 ?\nLes médicaments immunomodulateurs affectent-ils les CD45 ?",
"url": "https://questionsmedicales.fr/mesh/D017493#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigènes CD45",
"description": "Quelles complications peuvent survenir avec des anomalies des CD45 ?\nLes anomalies des CD45 augmentent-elles le risque de cancer ?\nComment les CD45 affectent-ils la transplantation ?\nLes complications sont-elles réversibles ?\nLes CD45 sont-ils liés à des complications neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D017493#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigènes CD45",
"description": "Quels sont les facteurs de risque pour les anomalies des CD45 ?\nL'âge influence-t-il les niveaux de CD45 ?\nLe mode de vie affecte-t-il les CD45 ?\nLes maladies chroniques augmentent-elles le risque d'anomalies des CD45 ?\nLe stress psychologique est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D017493#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des antigènes CD45 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par cytométrie en flux pour évaluer l'expression des CD45."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les CD45 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunologiques et des analyses de sang sont utilisés pour évaluer les CD45."
}
},
{
"@type": "Question",
"name": "Les CD45 sont-ils impliqués dans des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies des CD45 sont liées à des maladies auto-immunes et des cancers."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance des CD45 dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CD45 aident à identifier les sous-populations de lymphocytes dans diverses pathologies."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les CD45 dans les biopsies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CD45 peuvent être détectés dans les biopsies par immunohistochimie."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux anomalies des CD45 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, infections fréquentes et troubles immunitaires."
}
},
{
"@type": "Question",
"name": "Les anomalies des CD45 provoquent-elles des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des symptômes liés à des troubles immunitaires ou hématologiques."
}
},
{
"@type": "Question",
"name": "Comment les CD45 affectent-ils la réponse immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CD45 régulent l'activation des lymphocytes, influençant la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de CD45 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types de CD45 peuvent être associés à des symptômes variés."
}
},
{
"@type": "Question",
"name": "Les CD45 sont-ils liés à des symptômes neurologiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent un lien potentiel entre CD45 et certains troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des CD45 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et la gestion des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles les CD45 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent moduler l'expression des CD45 et renforcer l'immunité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques pour les CD45 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des dépistages peuvent aider à prévenir les anomalies des CD45."
}
},
{
"@type": "Question",
"name": "L'alimentation affecte-t-elle les CD45 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé immunitaire et l'expression des CD45."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les CD45 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter l'expression des CD45 et la fonction immunitaire."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les anomalies des CD45 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs et des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines affectent-elles les CD45 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les transfusions peuvent modifier l'expression des antigènes CD45 sur les leucocytes."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques influencent-elles les CD45 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques peuvent corriger les anomalies des CD45 dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon les CD45 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil CD45 du patient."
}
},
{
"@type": "Question",
"name": "Les médicaments immunomodulateurs affectent-ils les CD45 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent moduler l'expression des CD45 et améliorer la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des CD45 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections récurrentes et des troubles hématologiques."
}
},
{
"@type": "Question",
"name": "Les anomalies des CD45 augmentent-elles le risque de cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies des CD45 sont associées à un risque accru de cancers hématologiques."
}
},
{
"@type": "Question",
"name": "Comment les CD45 affectent-ils la transplantation ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies des CD45 peuvent compliquer la compatibilité et le rejet des greffes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Les CD45 sont-ils liés à des complications neurologiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre anomalies des CD45 et certaines complications neurologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des CD45 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des infections chroniques et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux de CD45 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter l'expression des CD45 et la fonction immunitaire."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il les CD45 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie malsain, comme le tabagisme, peut influencer l'expression des CD45."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles le risque d'anomalies des CD45 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies chroniques peuvent perturber l'expression des CD45 et la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Le stress psychologique est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress psychologique peut affecter l'expression des CD45 et la santé immunitaire."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2026
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Publications dans "Antigènes CD45" :
3 publications dans cette catégorie
Affiliations :
The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.
Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA.
Publications dans "Antigènes CD45" :
3 publications dans cette catégorie
Affiliations :
The HLA Research Group, Department of Veterans Affairs Health Care System, Brain Sciences Center, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN, 55417, USA. omega@umn.edu.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA. omega@umn.edu.
Institute for Health Informatics, University of Minnesota Medical School, Minneapolis, MN, USA. omega@umn.edu.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Tasly Research Institute, Tasly Holding Group Co., Ltd, Tianjin, China.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Sciences, BK21 Plus Biomedical Science Project, Seoul National University College of Medicine, Seoul, South Korea. buhm.han@snu.ac.kr.
Department of Convergence Medicine, University of Ulsan College of Medicine & Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea. buhm.han@snu.ac.kr.
Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, South Korea. buhm.han@snu.ac.kr.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Education and Data Science, Lewis Katz School of Medicine, Philadelphia, PA, USA.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, PA, USA.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA, USA.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Publications dans "Antigènes CD45" :
2 publications dans cette catégorie
Affiliations :
Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, USA.
Publications dans "Antigènes CD45" :
1 publication dans cette catégorie
Affiliations :
Department of Dermatology, Hospital General "Dr. Manuel Gea González", Mexico City, MEX.
Publications dans "Antigènes CD45" :
1 publication dans cette catégorie
Affiliations :
Department of Dermatology, Hospital General "Dr. Manuel Gea González", Mexico City, MEX.
Publications dans "Antigènes CD45" :
1 publication dans cette catégorie
Affiliations :
Department of Dermatology, Hospital General "Dr. Manuel Gea González", Mexico City, MEX.
Publications dans "Antigènes CD45" :
1 publication dans cette catégorie
Affiliations :
Instituto de Ciencias Biomédicas, Universidad Autónoma de Ciudad Juárez, Mexico City, MEX.
Publications dans "Antigènes CD45" :
Gynaecological tumours that threaten the health of women, especially when advanced and recurrent, have remained mostly intractable to existing treatments. Therefore, new therapeutic targets are urgent...
KIR3DL1 is a polymorphic inhibitory Natural Killer (NK) cell receptor that recognizes Human Leukocyte Antigen (HLA) class I allotypes that contain the Bw4 motif. Structural analyses have shown that in...
The aim of this study was to determine the Human Leukocyte Antigen (HLA) class II (...
Resistance to antimicrobial peptides (AMPs) plays an important role in allowing...
Antibody-mediated rejection (AMR) is the most common cause of immune-mediated allograft failure after kidney transplant and impacts allograft survival. Previous sensitization is a major risk factor fo...
A 48-year-old, caucasian woman with end-stage kidney disease (ESKD) secondary to autosomal dominant polycystic kidney disease (ADPKD) on peritoneal dialysis was registered in deceased donor waitlist. ...
Shared eplets between the patient husband and donor was responsible for the alloimmune response and early development of DSAs. This case highlights the importance of early monitoring DSA levels in hig...
Dendritic cells (DCs) play a central role in initiating and shaping the adaptive immune response, thanks to their ability to uptake antigens and present them to T cells. Once in the lymph node (LN), D...
Human leukocyte antigen (HLA) sensitization is a major barrier to kidney transplantation induced by exposure to alloantigens through pregnancy, blood product exposure and previous transplantations. De...
Newer desensitization strategies such as imlifidase [immunoglobulin G (IgG) endopeptidase] rapidly inactivates IgG molecules and creates an "antibody-free zone", representing an important advancement ...
Use of these agents alone or in combination will likely improve the efficacy and durability of desensitization therapies, improving access to kidney transplantation for immunologically disadvantaged p...
The development of therapeutics for patients who are positive for specific human leukocyte antigen (HLA) subtypes evokes the question of whether certain racial and ethnic groups are more or less likel...
To determine whether racial and ethnic inequities were present with regard to trial eligibility in trials investigating a therapeutic restricted to patients with specific HLA subtypes....
This cross-sectional study included all clinical trials registered in ClinicalTrials.gov through March 18, 2022, that investigated an interventional study of a therapeutic strategy and restricted part...
The type of therapeutics used in trials, the condition under study, the HLA subtypes used, and the likelihood of being enrolled in such a trial according to race and ethnicity....
Of 2135 trials identified, 263 met inclusion criteria. Overall, the estimated likelihood of being eligible for an HLA-based trial was 50.3%. Individuals of African American descent had the lowest like...
The findings of this cross-sectional study suggest that enrollment restrictions for clinical trials investigating novel HLA therapeutics may be associated with racial and ethnic inequities with regard...
The implementation of highly sensitive immune assays measuring anti-human leukocyte antigen (HLA) antibodies has modified alloimmune risk stratification and diagnosis of rejection. Nonetheless, anti-H...
Functional assays involving ex vivo polyclonal activation of mBC have been refined to allow the detection of HLA-specific mBC capable of producing anti-HLA Abs, using different and complementary detec...
Technological refinements have allowed the development of tests detecting HLA-specific mBC. Further evaluation of these assays in clinical trials, both for immune risk stratification and to assess tre...
Although numerous reports have studied the consequences of human leukocyte antigen (HLA) mismatching in renal transplantation, there are limited and outdated data analyzing this association in thoraci...
We performed a retrospective analysis of adult patients after heart transplant by using the United Network for Organ Sharing database from January 2005-July 2021. Total HLA and HLA-A, HLA-B and HLA-DR...
A total of 33,060 patients were included in this study. Recipients with a high degree of HLA mismatching had increased incidences of acute organ rejection. There were no significant differences in mor...
Our analysis suggests that HLA mismatch is not a significant predictor of survival in the modern era. Overall, the clinical implications of this study provide reassuring data for the continued use of ...